Search research articles
Contact Us
Filters
Showing results (61-70 of 208) with videos related to
Page
of 21
Sort By:
British Journal of Cancer
|
October 23, 2015
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
Frede Donskov, M Dror Michaelson, Igor Puzanov, et al.
Journal of Translational Medicine
|
April 18, 2020
The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019
Paolo A Ascierto, Sanjiv S Agarwala, Alexander Eggermont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 15, 2016
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Igor Puzanov, Mohammed M Milhem, David Minor, et al.
Journal for Immunotherapy of Cancer
|
May 30, 2024
Use of artificial intelligence chatbots in clinical management of immune-related adverse events
Hannah Burnette, Aliyah Pabani, Mitchell S von Itzstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma
Grant A McArthur, Igor Puzanov, Ravi Amaravadi, et al.
The New England Journal of Medicine
|
September 8, 2010
Inhibition of mutated, activated BRAF in metastatic melanoma
Keith T Flaherty, Igor Puzanov, Kevin B Kim, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
November 16, 2016
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition
Douglas B Johnson, Eirini Pectasides, Emily Feld, et al.
Investigational New Drugs
|
May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study
Stergios J Moschos, Shahneen Sandhu, Karl D Lewis, et al.
Annals of Surgical Oncology
|
June 26, 2016
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
Robert H I Andtbacka, Merrick Ross, Igor Puzanov, et al.
Cancer
|
June 8, 2012
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy
Daniel C Cho, Thomas E Hutson, Wolfram Samlowski, et al.
Page
of 21
Search research articles
Search
Showing results (61-70 of 208) with videos related to
Sort By:
Page
of 21
British Journal of Cancer
|
October 23, 2015
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients
Frede Donskov, M Dror Michaelson, Igor Puzanov, et al.
Journal of Translational Medicine
|
April 18, 2020
The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019
Paolo A Ascierto, Sanjiv S Agarwala, Alexander Eggermont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 15, 2016
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Igor Puzanov, Mohammed M Milhem, David Minor, et al.
Journal for Immunotherapy of Cancer
|
May 30, 2024
Use of artificial intelligence chatbots in clinical management of immune-related adverse events
Hannah Burnette, Aliyah Pabani, Mitchell S von Itzstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma
Grant A McArthur, Igor Puzanov, Ravi Amaravadi, et al.
The New England Journal of Medicine
|
September 8, 2010
Inhibition of mutated, activated BRAF in metastatic melanoma
Keith T Flaherty, Igor Puzanov, Kevin B Kim, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
November 16, 2016
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition
Douglas B Johnson, Eirini Pectasides, Emily Feld, et al.
Investigational New Drugs
|
May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study
Stergios J Moschos, Shahneen Sandhu, Karl D Lewis, et al.
Annals of Surgical Oncology
|
June 26, 2016
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
Robert H I Andtbacka, Merrick Ross, Igor Puzanov, et al.
Cancer
|
June 8, 2012
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy
Daniel C Cho, Thomas E Hutson, Wolfram Samlowski, et al.
Page
of 21